Track Humacyte's total revenue ($2.1M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowAs of Jun 2026
Trailing 12 months ending Jun 2026
Humacyte's total revenue stands at $2.1M as of June 2026. That compares with $8M in the prior-year period — down 73.6% year over year. That is below the Healthcare sector average of $110B. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Humacyte reported $2.1M in total revenue versus $8M a year earlier — a 73.6% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.
Humacyte sits lower the Healthcare benchmark ($110B) with a total revenue of $2.1M. That is roughly 100.0% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.
That compares with $8M in the prior-year period — down 73.6% year over year. Sustained growth in total revenue can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.
The history chart shows how Humacyte's total revenue evolved across reporting periods, while the comparison chart places HUMA next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.